Inimmune is a clinical-stage immunotherapy biotech company with a deep pipeline of vaccine adjuvants and immunotherapeutics advancing potential breakthroughs in human health. With a full suite of state-of-the-art preclinical labs and an extensive network of collaborations with top-tier researchers across the country, Inimmune has a growing pipeline of disruptive technologies and the capability to advance these from early discovery to clinical use. The leading R&D team’s performance has been validated with the awarding of several large National Institute of Health contracts and grants which directly contribute to the advancement of novel adjuvants and immunotherapies. Inimmune’s disease-modifying treatments are expected to make major impacts in the allergy, cancer and vaccine fields in the years to come for the betterment of humankind. Visit inimmune.com.
